SCHEMBL415760

SCHEMBL415760

CC(=O)O[C@H]1CC[C@]2(C)C3=C(CC[C@H]2C1(C)C)[C@]1(C)CC[C@H]([C@H](C)CCC=C(C)C)[C@@]1(C)CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
PTGES O14684 4/20 0.84
CRYAB P02511 2/20 0.75
LMNA P02545 1/20 0.75
FNTA P49354 1/20 0.69
FNTB P49356 1/20 0.69
MEN1 O00255 1/20 0.60
PLA2G1B P04054 1/20 0.60
DNMT1 P26358 1/20 0.60
BLM P54132 1/20 0.60
KMT2A Q03164 1/20 0.60
ATG4B Q9Y4P1 1/20 0.60
PREP P48147 1/20 0.59
PIN1 Q13526 1/20 0.59
BACE1 P56817 1/20 0.56
CRYAA P02489 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19194140 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL17431708 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL6130526 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL415761 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL5666302 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL2340127 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL20990912 0.92 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL4735043 0.92 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL21183478 0.92 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL21149075 0.92 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451132-A4 CHEMICAL SYNTHESIS UNIV WAIKATO (NZ) 2006-02-08 EP claimed
US-20050038301-A1 Producing vicinal diols; reacting with hydroxyl group donor and reducing acidic agent UNIVERSITY OF WAIKATO, THE (NZ) 2005-02-17 US claimed
EP-1451132-A1 CHEMICAL SYNTHESIS THE UNIVERSITY OF WAIKATO (NZ) 2004-09-01 EP claimed
WO-2003040066-A1 CHEMICAL SYNTHESIS THE UNIVERSITY OF WAIKATO (NZ) 2003-05-15 WO claimed
US-6315981-B1 USED FOR OBTAINING IMAGE OF AN INTERNAL REGION OF HUMANS IMARX THERAPEUTICS, INC. 2001-11-13 US claimed
EP-0760684-A4 GAS FILLED MICROSPHERES AS COMPUTED TOMOGRAPHY CONTRAST AGENTS IMARX PHARMACEUTICAL CORP (US) 2000-03-15 EP claimed
EP-0740528-A4 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP (US) 1998-04-01 EP claimed
US-5733572-A Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles IMARX PHARMACEUTICAL CORP. (US) 1998-03-31 US claimed
JP-H10500692-A 1998-01-20 JP claimed
EP-0797433-A4 GAS FILLED MICROSPHERES AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS IMARX PHARMACEUTICAL CORP (US) 1997-12-03 EP claimed
EP-0797433-A1 GAS FILLED MICROSPHERES AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS ImaRx Pharmaceutical Corp. (US) 1997-10-01 EP claimed
EP-0760684-A1 GAS FILLED MICROSPHERES AS COMPUTED TOMOGRAPHY CONTRAST AGENTS IMARX PHARMACEUTICAL CORP. (US) 1997-03-12 EP claimed
EP-0740528-A1 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP. (US) 1996-11-06 EP claimed
WO-1995032006-A1 GAS FILLED MICROSPHERES AS COMPUTED TOMOGRAPHY CONTRAST AGENTS IMARX, PHARMACEUTICAL CORP. (US) 1995-11-30 WO claimed
WO-1995024184-A1 GAS FILLED MICROSPHERES AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS UNGER EVAN C (US) 1995-09-14 WO claimed
WO-1995015118-A1 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP. (US) 1995-06-08 WO claimed
US-12427208-B2 Iodinated phenolic lipids and methods and cosolvent systems for iodination of phenolic lipids UNIVERSITY OF CINCINNATI (US) 2025-09-30 US disclosed
US-20250295806-A1 IMMUNOSTIMULATORY NANOPARTICLE UNIV CASE WESTERN RESERVE (US) 2025-09-25 US disclosed
WO-1995015118-A1 GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION IMARX PHARMACEUTICAL CORP. (US) 1995-06-08 WO disclosed
US-4684479-A Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures CAVITATION-CONTROL TECHNOLOGY, INC. 1987-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427208-B2 Iodinated phenolic lipids and methods and cosolvent systems for iodination of phenolic lipids FABP4, LCAT, HDLBP MAPT 2158/4885USP2 2851/4885ALDH1A1 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.